# 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

> **NCT00077415** · PHASE2 · COMPLETED · sponsor: **Cancer Therapeutics Research Group** · enrollment: 31 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** triapine

## Key facts

- **NCT ID:** NCT00077415
- **Lead sponsor:** Cancer Therapeutics Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-02
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2013-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077415, "3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00077415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*